Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Inozyme Pharma ( (INZY) ) has shared an announcement.
Inozyme Pharma announced positive interim results for its INZ-701 treatment from the ENERGY 1 trial and Expanded Access Program, demonstrating improved survival rates, reduced arterial calcifications, and improved heart function in infants and young children with ENPP1 Deficiency. The company completed enrollment in the ENERGY 3 pivotal trial and received regulatory guidance for the upcoming ASPIRE pivotal trial focused on ABCC6 Deficiency in children, highlighting significant advancements in their therapeutic programs and underscoring the potential impact on addressing unmet medical needs in these patient populations.
More about Inozyme Pharma
Inozyme Pharma is a clinical-stage biopharmaceutical company focusing on developing innovative treatments for rare diseases that affect bone health and blood vessel function.
YTD Price Performance: -1.75%
Average Trading Volume: 528,514
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $179.9M
See more data about INZY stock on TipRanks’ Stock Analysis page.
